Customer ExpansionSOPH added 35 new genomics customers to Sophia DDM in Q4, which was solid, partially offset by a ~4% smaller customer churn.
Market PotentialAnalyst maintains a positive view on SOPH shares due to the company's differentiated business model, large under-penetrated market, and solid balance sheet.
Revenue GrowthSOPH guided for a return to double-digit revenue growth in 2025 as the company is confident in its ability to turn on customers new to SOPH's DDM platform, particularly for the newer MSK-Access liquid biopsy application.
Volume GrowthSOPH reported a total analysis volume of 91K, which was a 16% increase year-over-year, outperforming expectations.